Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.
Ito K, Murotani K, Kubo A, Kunii E, Taniguchi H, Shindoh J, Asada K, Imaizumi K, Takahashi K, Karayama M, Okuno M, Inui N, Hataji O, Morikawa S, Hayai S, Suda T, Abe T, Tsuda T, Yamagichi T, Kimura T, Oya Y, Yoshida T, Hida T. Ito K, et al. Among authors: kubo a. Cancer Sci. 2020 Oct;111(10):3705-3713. doi: 10.1111/cas.14560. Epub 2020 Aug 5. Cancer Sci. 2020. PMID: 32639668 Free PMC article.
EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer.
Sasaki H, Okuda K, Shimizu S, Takada M, Kawahara M, Kitahara N, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Kubo A, Kawano O, Yukiue H, Yano M, Fujii Y. Sasaki H, et al. Among authors: kubo a. J Cancer Res Clin Oncol. 2009 Feb;135(2):313-8. doi: 10.1007/s00432-008-0464-5. Epub 2008 Aug 23. J Cancer Res Clin Oncol. 2009. PMID: 18726117
Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations.
Nishie K, Kawaguchi T, Tamiya A, Mimori T, Takeuchi N, Matsuda Y, Omachi N, Asami K, Okishio K, Atagi S, Okuma T, Kubo A, Maruyama Y, Kudoh S, Takada M. Nishie K, et al. Among authors: kubo a. J Thorac Oncol. 2012 Nov;7(11):1722-7. doi: 10.1097/JTO.0b013e31826913f7. J Thorac Oncol. 2012. PMID: 23059777 Free article.
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Kanazu M, Maruyama K, Ando M, Asami K, Ishii M, Uehira K, Minomo S, Matsuda Y, Kawaguchi T, Atagi S, Ogawa Y, Kusunoki Y, Takada M, Kubo A. Kanazu M, et al. Among authors: kubo a. Clin Lung Cancer. 2014 May;15(3):182-7. doi: 10.1016/j.cllc.2014.01.001. Epub 2014 Jan 9. Clin Lung Cancer. 2014. PMID: 24518101 Clinical Trial.
The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH. Hasegawa Y, et al. Among authors: kubo a. Oncologist. 2015 Mar;20(3):307-15. doi: 10.1634/theoncologist.2014-0285. Epub 2015 Feb 5. Oncologist. 2015. PMID: 25657199 Free PMC article.
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.
Watanabe M, Kawaguchi T, Isa S, Ando M, Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Sakamoto K, Matsumura A, Koh Y. Watanabe M, et al. Among authors: kubo a. Clin Cancer Res. 2015 Aug 1;21(15):3552-60. doi: 10.1158/1078-0432.CCR-14-2151. Epub 2015 Apr 16. Clin Cancer Res. 2015. PMID: 25882755
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Mitsuoka S, Kawaguchi T, Kubo A, Isa S, Asai K, Uji M, Watanabe T, Sawa K, Yoshimoto N, Oka T, Nakai T, Suzumura T, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Kudoh S, Hirata K. Mitsuoka S, et al. Among authors: kubo a. Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18. Expert Opin Pharmacother. 2016. PMID: 26781399 Review.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I. Takeda M, et al. Among authors: kubo a. Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1. Cancer. 2016. PMID: 26828788 Free article. Clinical Trial.
Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation.
Fujita M, Matsumoto T, Hirano R, Uchino J, Hirota T, Yamaguchi E, Kubo A, Yokoi T, Nabeshima K, Watanabe K. Fujita M, et al. Among authors: kubo a. Intern Med. 2016;55(12):1621-4. doi: 10.2169/internalmedicine.55.6592. Epub 2016 Jun 15. Intern Med. 2016. PMID: 27301516 Free article.
1,403 results